Compare UROY & MOBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UROY | MOBI |
|---|---|---|
| Founded | 2017 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.6M | 399.7M |
| IPO Year | 2026 | 2026 |
| Metric | UROY | MOBI |
|---|---|---|
| Price | $4.14 | $13.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 75.9K |
| Earning Date | 03-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $279.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,584.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.51 | $10.34 |
| 52 Week High | $5.52 | $15.19 |
| Indicator | UROY | MOBI |
|---|---|---|
| Relative Strength Index (RSI) | 73.94 | 57.67 |
| Support Level | $3.40 | $12.66 |
| Resistance Level | $4.48 | $15.19 |
| Average True Range (ATR) | 0.27 | 0.85 |
| MACD | 0.13 | 0.27 |
| Stochastic Oscillator | 91.37 | 71.79 |
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.